Logo Logo
Hilfe
Hilfe
Switch Language to English

Palm, Jonas; Holdenrieder, Stefan; Hoffmann, Georg; Hoerer, Jürgen; Shi, Ruibing; Klawonn, Frank und Ewert, Peter (2021): Predicting Major Adverse Cardiovascular Events in Children With Age-Adjusted NT-proBNP. In: Journal of the American College of Cardiology, Bd. 78, Nr. 19: S. 1890-1900

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

BACKGROUND N-terminal pro-B-type natriuretic peptide (NT-proBNP) is frequently used as a valuable prognostic biomarker in cardiac diseases. In children, however, it has not been established because of its strong age dependency. To overcome this obstacle, we recently introduced the zlog value of N-terminal pro-B-type natriuretic peptide (zlog-proBNP) as an age-adjusted reference. OBJECTIVES This study evaluates the prognostic power of ztog-proBNP for the occurrence of major adverse cardiovascular events (MACE) throughout childhood in patients with congenital heart diseases (CHD). METHODS A total of 910 children with CHD (median age 5 months;range 0.0-18.0 years) were included. MACE was defined as death, resuscitation, mechanical circulatory support, or hospitalization caused by cardiac decompensation. Because the physiological NT-proBNP concentration decreases significantly during childhood, ztog values were applied for an age-independent evaluation. RESULTS MACE occurred in 138 children during a median follow-up of 6 months (range 1 day to 7.6 years). High zlog-proBNP values (>+3.0) were most strongly associated with adverse events (n = 93;adjusted HR: 21.1;95% CI: 2.9-154.2;P < 0.001). Among all evaluated indicators, ztog-proBNP was the best predictor for MACE (adjusted HR: 1.52;95% CI: 1.31-1.76;P < 0.001) along with age and predictively superior to absolute NT-proBNP values. A cutoff value of +1.96 (age-independent upper limit of the physiological NT-proBNP concentration) achieved a negative predictive value of >96%. CONCLUSIONS Ztog-proBNP overcomes the strong age dependency of NT-proBNP and is a powerful prognostic marker for age-independent exclusion and prediction of MACE in children with CHD. We therefore expect zlog-proBNP to play a pivotal rote in the future management of children with heart diseases. (C) 2021 by the American College of Cardiology Foundation.

Dokument bearbeiten Dokument bearbeiten